Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models

Introduction Targeting receptor tyrosine kinases (RTKs) with kinase inhibitors is a clinically validated anti-cancer approach. However, blocking one signaling pathway is often not sufficient to cause tumor regression and the effectiveness of individual inhibitors is often short-lived. As alterations...

Full description